Thymosin Alpha-1 (TA-1)

Research Papers and Clinical Trials

The research on Thymosin Alpha-1 (TA-1) spans several decades and covers multiple therapeutic areas, with the strongest evidence base in hepatitis treatment and emerging applications in sepsis, cancer, and COVID-19 prevention.

Hepatitis Research

Much of the published research focuses on hepatitis B and C treatment. A 2018 prospective multicenter randomized open-label study examined combining entecavir with thymosin alpha-1 in patients with HBV-related compensated cirrhosis. Earlier work from 2010 investigated TA-1's effects on T-helper cell cytokine production in hepatitis B patients who were e antigen-positive.

For hepatitis C, a 2004 study published in the Journal of the Pakistan Medical Association evaluated TA-1 in combination with interferon alpha and ribavirin in chronic hepatitis C patients who had not responded to or relapsed after interferon plus ribavirin therapy. Research from 2010 provided broader analysis of TA-1's promise in hepatitis C treatment.

Foundational research from 1991 identified low thymosin alpha-1 concentrations in patients chronically infected with hepatitis B virus, helping establish the rationale for therapeutic supplementation.

Immunological and Cancer Research

Earlier preclinical studies explored TA-1's immunomodulatory properties. A 1985 study examined TA-1's effects on cellular responses and T-cell subsets in mice with experimental autoimmune thyroiditis. Research from 1988 investigated thymic factor-induced reduction of lung metastases in mice with fibrosarcoma. A 1990 study clarified that TA-1's enhancement of lymphocyte proliferation operates independently of prostaglandin E2 pathways.

Current Clinical Trials

Several clinical trials are evaluating TA-1 across different indications:

Sepsis: A completed Phase 3 trial (NCT02867267) assessed TA-1's efficacy and safety for sepsis treatment.

Cancer: Multiple trials are investigating TA-1 in non-small cell lung cancer, including a Phase 2 study in metastatic EGFR wild-type patients (NCT02906150) and a Phase 1/2 trial in EGFR mutation-positive patients receiving standard care (NCT02906163). A Phase 2 trial is currently recruiting patients with advanced microsatellite stable/proficient mismatch repair colorectal cancer (NCT06829355).

COVID-19: A completed Phase 2 trial (NCT04428008) evaluated TA-1 for preventing COVID-19 infection in renal dialysis patients.

Note: Several trials show "unknown" status, indicating uncertainty about completion or results availability. Sample sizes and detailed study designs are not available from the provided evidence. Patients should consult healthcare providers about TA-1's appropriateness for their specific conditions, as this represents research-stage rather than established therapy for most indications.